

Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)

NCT02342444

Status	RECRUITING
Phase	Phase 4
Sponsor	Oregon Health and Science University
Enrollment	606 participants

Key Eligibility Criteria

Inclusion (3)

- Admitted patients requiring prophylactic dosing of enoxaparin (Lovenox)
- Admitted to the trauma or surgical service
- Age greater than 15 years

Exclusion (5)

- Unable to obtain consent from patient or authorized representative
- Presence of intracranial hemorrhage
- Receiving therapeutic dose of enoxaparin (Lovenox)
- Receiving other forms of anticoagulation
- Presence of renal failure requiring non-standard dosing regimen

Locations (1 total)

Oregon Health & Science University, Portland, Oregon, United States